Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Clinical High Risk for Psychosis Clinical Trial Network (U01 Clinical Trial Required)
Department of Health and Human Services National Institutes of Health
Posted on:
Application Deadline:
Expired
Type
Research/project funding
Reference Number
RFA-MH-24-150
To use a subset of drug development tools, which are being assessed in the AMP SCZ observational study, in a PoP trial with CHR individuals to determine the ability to detect a biological and/or clinical signal with the compound or compounds selected to use within a 12-16 week study period. The PoP trial will assess the performance of the PSYCHS, other clinical outcome measures, and biological measures. The compound or compounds that are selected for testing in the CHR Clinical Trial Network will affect a pathophysiologically relevant mechanism and have the potential to produce a detectable signal on biological and clinical outcome measures within a 12-16 week period of study.
Categories: Health.
Categories: Health.
United States